Europe Glycated Albumin Assay Market Size, Share & Industry Trends Analysis Report By Application (Type 2 Diabetes, Type 1 Diabetes, and Prediabetes), By End User, By Country and Growth Forecast, 2023 - 2030

Europe Glycated Albumin Assay Market Size, Share & Industry Trends Analysis Report By Application (Type 2 Diabetes, Type 1 Diabetes, and Prediabetes), By End User, By Country and Growth Forecast, 2023 - 2030


The Europe Glycated Albumin Assay Market would witness market growth of 7.9% CAGR during the forecast period (2023-2030).

Glycemic regulation is necessary for diabetes treatment. Numerous estimations provide pointers, including glycated hemoglobin (HbA1c), 1, 5-anhydroglucitol (1,5AG), and glycated albumin. The glycemic level during the first three months of diabetes frequency is shown by glycated hemoglobin (HbA1c). For the confirmation of temporary restorative viability, while starting diabetes treatment, this test is essential.

In the near future, the market is expected to experience rapid expansion and improvements. The importance of glycated albumin testing in clinical practice is anticipated to rise due to the rising prevalence of diabetes and the requirement for efficient glycemic control monitoring. This assay has several benefits compared to conventional glycated hemoglobin (HbA1c) testing, including quicker turnaround times, sensitivity to recent glycemic alterations, and independence from variables like erythrocyte durability and specific hemoglobin variations.

Nearly one in seven UK residents are expected to be over the age of 75 by 2040, according to a government assessment titled “Future of an aging population” (UK). There will be 1.42 million more homes with a head of household who is 85 years of age or older by 2037, a rise of 161% over the previous 25 years. Over 5.5 million more people will be added to the working-age population between the ages of 50 and the state pension age (SPA), from 26% in 2012 to 34% in 2050. According to a UN assessment of France aging policy, France, like other European nations, is experiencing a steady and large rise in the population of senior people. In 2012, there were 15 million persons in France over the age of 60. In 2060, this number will increase to 24 million. It is anticipated that the market will grow as a result of the aging population in these regional nations which raise the risk of diabetes.

The Germany market dominated the Europe Glycated Albumin Assay Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $24,356.5 Thousands by 2030. The UK market is exhibiting a CAGR of 7% during (2023 - 2030). Additionally, The France market would experience a CAGR of 8.7% during (2023 - 2030).

Based on Application, the market is segmented into Type 2 Diabetes, Type 1 Diabetes, and Prediabetes. Based on End User, the market is segmented into Hospitals & Diabetic Care Center, Diagnostic Laboratory, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Asahi Kasei Pharma Corporation (Asahi Kasei Corporation), EKF Diagnostics Holdings plc, Weldon Biotech India Private Limited, Hzymes Biotechnology Co., Ltd., Beijing Strong Biotechnologies, Inc., Diazyme Laboratories, Inc. (General Atomics), Abbexa Limited, Biomatik Corporation, Abnova Corporation and Geno Technology, Inc.

Scope of the Study

Market Segments covered in the Report:

By Application
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Prediabetes
By End User
  • Hospitals & Diabetic Care Center
  • Diagnostic Laboratory
  • Others
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • Asahi Kasei Pharma Corporation (Asahi Kasei Corporation)
  • EKF Diagnostics Holdings plc
  • Weldon Biotech India Private Limited
  • Hzymes Biotechnology Co., Ltd.
  • Beijing Strong Biotechnologies, Inc.
  • Diazyme Laboratories, Inc. (General Atomics)
  • Abbexa Limited
  • Biomatik Corporation
  • Abnova Corporation
  • Geno Technology, Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Glycated Albumin Assay Market, by Application
1.4.2 Europe Glycated Albumin Assay Market, by End User
1.4.3 Europe Glycated Albumin Assay Market, by Country
1.5 Methodology for the research
Chapter 2. Market At a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Europe Glycated Albumin Assay Market by Application
4.1 Europe Type 2 Diabetes Market by Country
4.2 Europe Type 1 Diabetes Market by Country
4.3 Europe Prediabetes Market by Country
Chapter 5. Europe Glycated Albumin Assay Market by End User
5.1 Europe Hospitals & Diabetic Care Center Market by Country
5.2 Europe Diagnostic Laboratory Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Glycated Albumin Assay Market by Country
6.1 Germany Glycated Albumin Assay Market
6.1.1 Germany Glycated Albumin Assay Market by Application
6.1.2 Germany Glycated Albumin Assay Market by End User
6.2 UK Glycated Albumin Assay Market
6.2.1 UK Glycated Albumin Assay Market by Application
6.2.2 UK Glycated Albumin Assay Market by End User
6.3 France Glycated Albumin Assay Market
6.3.1 France Glycated Albumin Assay Market by Application
6.3.2 France Glycated Albumin Assay Market by End User
6.4 Russia Glycated Albumin Assay Market
6.4.1 Russia Glycated Albumin Assay Market by Application
6.4.2 Russia Glycated Albumin Assay Market by End User
6.5 Spain Glycated Albumin Assay Market
6.5.1 Spain Glycated Albumin Assay Market by Application
6.5.2 Spain Glycated Albumin Assay Market by End User
6.6 Italy Glycated Albumin Assay Market
6.6.1 Italy Glycated Albumin Assay Market by Application
6.6.2 Italy Glycated Albumin Assay Market by End User
6.7 Rest of Europe Glycated Albumin Assay Market
6.7.1 Rest of Europe Glycated Albumin Assay Market by Application
6.7.2 Rest of Europe Glycated Albumin Assay Market by End User
Chapter 7. Company Profiles
7.1 Asahi Kasei Pharma Corporation (Asahi Kasei Corporation)
7.1.1 Company Overview
7.1.2 SWOT Analysis
7.1.3 Financial Analysis
7.1.4 Segmental and Regional Analysis
7.1.5 Research & Development Expenses
7.2 EKF Diagnostics Holdings plc
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 SWOT Analysis
7.3 Weldon Biotech India Private Limited
7.3.1 Company Overview
7.3.2 SWOT Analysis
7.4 Hzymes Biotechnology Co., Ltd.
7.4.1 Company Overview
7.5 Beijing Strong Biotechnologies, Inc.
7.5.1 Company Overview
7.5.2 SWOT Analysis
7.6 Abbexa Limited
7.6.1 Company Overview
7.6.2 SWOT Analysis
7.7 Biomatik Corporation
7.7.1 Company Overview
7.7.2 SWOT Analysis
7.8 Abnova Corporation
7.8.1 Company Overview
7.8.2 SWOT Analysis
7.9 Geno Technology, Inc.
7.9.1 Company Overview
7.9.2 SWOT Analysis
7.10. Diazyme Laboratories, Inc. (General Atomics)
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements:
7.10.3 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings